-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ss7KXaUTOKuNGatxFdZ6QgQpH/PD/wMt3eMLrlKW8zvKypYxNA0mp1tHTx4fe1a8 3uS+N+yv1g8uFEqx22+wkg== 0000950123-08-002665.txt : 20080307 0000950123-08-002665.hdr.sgml : 20080307 20080307130853 ACCESSION NUMBER: 0000950123-08-002665 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080304 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20080307 DATE AS OF CHANGE: 20080307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BARR PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000010081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221927534 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09860 FILM NUMBER: 08673469 BUSINESS ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 BUSINESS PHONE: 201-930-3300 MAIL ADDRESS: STREET 1: 225 SUMMIT AVE CITY: MONTVALE STATE: NJ ZIP: 07645-1523 FORMER COMPANY: FORMER CONFORMED NAME: BARR LABORATORIES INC DATE OF NAME CHANGE: 19920703 8-K 1 y51068e8vk.htm FORM 8-K FORM 8-K
 

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) March 4, 2008
BARR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  1-9860
(Commission
File Number) 		  42-1612474
(IRS Employer
Identification No.)
     
225 Summit Avenue, Montvale, NJ
(Address of principal executive offices) 		  07645
(Zip code)
(201) 930-3300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02(c) Appointment of Principal Officer.
     On March 4, 2008, Barr Pharmaceuticals, Inc. (the “Company”) appointed Sigurd Kirk, the Company’s Senior Vice President and Corporate Controller, as the Company’s Chief Accounting Officer. This responsibility was previously handled by William McKee who remains the Company’s Executive Vice President and Chief Financial Officer. This appointment was made in connection with the growth of the finance department and the growing complexity and scope of Mr. McKee’s responsibilities in managing the Company’s global finances.
     Mr. Kirk joined the Company in 2003 and has held positions of increasing responsibility in the accounting and finance functions within the finance department. Mr. Kirk began his career at Deloitte & Touche as an Audit Manager and, immediately prior to joining the Company, served as Senior Vice President of Finance & Operations for Bolt Inc., an Internet media company.

 

 

SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  BARR PHARMACEUTICALS, INC.
 		  
Date: March 7, 2008  /s/ William T. McKee    
  William T. McKee   
  Executive Vice President and Chief Financial Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----